Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 3
2004 2
2005 5
2006 5
2007 4
2008 7
2009 5
2010 5
2011 10
2012 10
2013 12
2014 11
2015 11
2016 8
2017 9
2018 1
2019 5
2020 7
2021 9
2022 7
2023 6
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

125 results

Results by year

Filters applied: . Clear all
Page 1
Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report From the Children's Oncology Group AAML1331 Trial.
Kutny MA, Alonzo TA, Abla O, Rajpurkar M, Gerbing RB, Wang YC, Hirsch BA, Raimondi S, Kahwash S, Hardy KK, Hardy S, Meshinchi S, Gamis AS, Kolb EA, Feusner JH, Gregory J Jr. Kutny MA, et al. Among authors: gerbing rb. JAMA Oncol. 2022 Jan 1;8(1):79-87. doi: 10.1001/jamaoncol.2021.5206. JAMA Oncol. 2022. PMID: 34762093 Free PMC article. Clinical Trial.
Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531.
Pollard JA, Guest E, Alonzo TA, Gerbing RB, Loken MR, Brodersen LE, Kolb EA, Aplenc R, Meshinchi S, Raimondi SC, Hirsch B, Gamis AS. Pollard JA, et al. Among authors: gerbing rb. J Clin Oncol. 2021 Oct 1;39(28):3149-3160. doi: 10.1200/JCO.20.03048. Epub 2021 May 28. J Clin Oncol. 2021. PMID: 34048275 Free PMC article. Clinical Trial.
CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group.
Tarlock K, Lamble AJ, Wang YC, Gerbing RB, Ries RE, Loken MR, Brodersen LE, Pardo L, Leonti A, Smith JL, Hylkema TA, Woods WG, Cooper TM, Kolb EA, Gamis AS, Aplenc R, Alonzo TA, Meshinchi S. Tarlock K, et al. Among authors: gerbing rb. Blood. 2021 Sep 30;138(13):1137-1147. doi: 10.1182/blood.2020009652. Blood. 2021. PMID: 33951732 Free PMC article. Clinical Trial.
Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.
Gamis AS, Alonzo TA, Meshinchi S, Sung L, Gerbing RB, Raimondi SC, Hirsch BA, Kahwash SB, Heerema-McKenney A, Winter L, Glick K, Davies SM, Byron P, Smith FO, Aplenc R. Gamis AS, et al. Among authors: gerbing rb. J Clin Oncol. 2014 Sep 20;32(27):3021-32. doi: 10.1200/JCO.2014.55.3628. J Clin Oncol. 2014. PMID: 25092781 Free PMC article. Clinical Trial.
Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis.
Zarnegar-Lumley S, Alonzo TA, Gerbing RB, Othus M, Sun Z, Ries RE, Wang J, Leonti A, Kutny MA, Ostronoff F, Radich JP, Appelbaum FR, Pogosova-Agadjanyan EL, O'Dwyer K, Tallman MS, Litzow M, Atallah E, Cooper TM, Aplenc RA, Abdel-Wahab O, Gamis AS, Luger S, Erba H, Levine R, Kolb EA, Stirewalt DL, Meshinchi S, Tarlock K. Zarnegar-Lumley S, et al. Among authors: gerbing rb. Blood Adv. 2023 Oct 10;7(19):5941-5953. doi: 10.1182/bloodadvances.2022008282. Blood Adv. 2023. PMID: 37267439 Free PMC article.
Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood KMT2A-Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Münster Study Group.
van Weelderen RE, Klein K, Harrison CJ, Jiang Y, Abrahamsson J, Arad-Cohen N, Bart-Delabesse E, Buldini B, De Moerloose B, Dworzak MN, Elitzur S, Fernández Navarro JM, Gerbing RB, Goemans BF, de Groot-Kruseman HA, Guest E, Ha SY, Hasle H, Kelaidi C, Lapillonne H, Leverger G, Locatelli F, Masetti R, Miyamura T, Norén-Nyström U, Polychronopoulou S, Rasche M, Rubnitz JE, Stary J, Tierens A, Tomizawa D, Zwaan CM, Kaspers GJL. van Weelderen RE, et al. Among authors: gerbing rb. J Clin Oncol. 2023 Jun 1;41(16):2963-2974. doi: 10.1200/JCO.22.02120. Epub 2023 Mar 30. J Clin Oncol. 2023. PMID: 36996387 Free PMC article.
Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia.
Huang BJ, Smith JL, Farrar JE, Wang YC, Umeda M, Ries RE, Leonti AR, Crowgey E, Furlan SN, Tarlock K, Armendariz M, Liu Y, Shaw TI, Wei L, Gerbing RB, Cooper TM, Gamis AS, Aplenc R, Kolb EA, Rubnitz J, Ma J, Klco JM, Ma X, Alonzo TA, Triche T Jr, Meshinchi S. Huang BJ, et al. Among authors: gerbing rb. Nat Commun. 2022 Sep 19;13(1):5487. doi: 10.1038/s41467-022-33244-6. Nat Commun. 2022. PMID: 36123353 Free PMC article.
Prognostic Impact of Co-occurring Mutations in FLT3-ITD Pediatric Acute Myeloid Leukemia.
Tarlock K, Gerbing RB, Ries RE, Smith JL, Leonti AR, Huang BJ, Kirkey DC, Robinson L, Peplinski JH, Lange B, Cooper TM, Gamis AS, Kolb EA, Aplenc R, Pollard JA, Meshinchi S. Tarlock K, et al. Among authors: gerbing rb. Blood Adv. 2024 Jan 31:bloodadvances.2023011980. doi: 10.1182/bloodadvances.2023011980. Online ahead of print. Blood Adv. 2024. PMID: 38295280
Structural variants involving MLLT10 fusion are associated with adverse outcomes in pediatric acute myeloid leukemia.
Abla O, Ries RE, Triche T Jr, Gerbing RB, Hirsch B, Raimondi S, Cooper T, Farrar JE, Buteyn N, Harmon LM, Wen H, Deshpande AJ, Kolb EA, Gamis AS, Aplenc R, Alonzo T, Meshinchi S. Abla O, et al. Among authors: gerbing rb. Blood Adv. 2024 Apr 23;8(8):2005-2017. doi: 10.1182/bloodadvances.2023010805. Blood Adv. 2024. PMID: 38306602 Free PMC article.
125 results